THRIVE-132: Therapy for Reduction in VOC Readmissions with Inclacumab
The THRIVE-132 study is determining the safety and efficacy of a possible treatment to prevent readmission for a vaso-occlusive crises with a single dose of Inclacumab, an inves...
12 years or older
Clinical
No
3
All types of SCD
United States
Italy
Kenya
...
An Electronic Patient Reported Pain Assessment in Sickle Cell
A study that aims to gather insights into painful crises in people living with sickle cell disease.
18 years or older
Digital
Yes
N/A
SCD type SS
SCD type Sβ0 thalassemia
Hibiscus Study: An oral investigational medication for SCD
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD. The primary purpose of the study is to evaluate the safety and effect...
12 to 65
Clinical
Yes
2/3
All types of SCD
United States
Canada
Europe
THRIVE-131: A study to potentially reduce VOCs in sickle cell
The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell diseas
12 years or older
Clinical
Yes
3
SCD type SS
SCD type SC
SCD type Sβ0 thalassemia
....
USA
Lebanon
Brazil
...
06 Jan 2023
Graphite Bio has cited a “serious adverse event in the first patient dosed” with its gene therapy nulabeglogene autogedtemcel (nula-cel) and paused its lead program.
Learn more
20 Sep 2022
The free program helps individuals become more care-prepared through information, resources, connections, counseling and support.
Learn more
16 Sep 2022
A recent analysis of Medicaid claims data found that individuals with sickle cell disease are seeing hematologists at a lower rate than patients with other chronic genetic diseases.
Learn moreWe send occasional updates that feature new trials, and other great tips. We will not spam you.
